Human ADAM Metallopeptidase With Thrombospondin Type 1 Motif 4 (ADAMTS4) CLIA Kit

Product specifications

CLIA Kits

ADAM Metallopeptidase With Thrombospondin Type 1 Motif 4 (ADAMTS4)

Human

Chemiluminescent

Quantitative

Sandwich

0.312 ng/ml - 20 ng/ml

< 0.134 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

5 × 96 tests

10 × 96 tests

Lyophilized

CLIA

Serum, plasma, tissue homogenates and other biological fluids.

Shipped within 5-20 working days.

 Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

KIAA0688, Type 1 Motif 4,A Disintegrin And Metalloproteinase With Thrombospondin Motifs 4 ,Aggrecanase-1,ADAM-TS4,ADAMTS-4

CLIA Kits ADAMTS4

RUO

The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.   This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

ADAMTS4, also known as A Disintegrin And Metalloproteinase with Thrombospondin Motifs 4, is a member of the ADAMTS protein family. ADAMTS4 contains multiple domains, including a metalloproteinase domain responsible for its enzymatic activity, as well as thrombospondin type-1 (TSP-1) motifs. ADAMTS4 is primarily known for its role in extracellular matrix remodeling, particularly in the breakdown of aggrecan, a large proteoglycan found in cartilage. ADAMTS4 cleaves aggrecan at specific sites, leading to the degradation of cartilage matrix and contributing to the pathogenesis of osteoarthritis and other joint-related disorders. It is one of the key enzymes involved in cartilage degradation in osteoarthritis.ADAMTS4 has been implicated in various diseases, particularly osteoarthritis. Elevated levels of ADAMTS4 expression have been observed in osteoarthritic cartilage, synovial fluid, and serum, suggesting its involvement in the disease process. Inhibition of ADAMTS4 activity has been explored as a potential therapeutic strategy for osteoarthritis to prevent cartilage degradation.Research on ADAMTS4 has implications for understanding the pathogenesis of osteoarthritis and other joint-related disorders. Targeting ADAMTS4 activity or expression may represent a promising therapeutic approach for these conditions. Additionally, further research into the regulation and function of ADAMTS4 may provide insights into its roles in normal physiology and other diseases.

Related Products

Human ADAMTS4(A disintegrin and metalloproteinase with thrombospondin motifs 4) ELISA Kit

Ver Producto

Rat Adamts4(A disintegrin and metalloproteinase with thrombospondin motifs 4) ELISA Kit

Ver Producto

ADAM Metallopeptidase With Thrombospondin Type 1 Motif 4 (ADAMTS4) Antibody

ADAMTS4 Antibody is a Rabbit Polyclonal antibody against ADAMTS4. This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The enzyme encoded by this gene lacks a C-terminal TS motif. It is responsible for the degradation of aggrecan, a major proteoglycan of cartilage, and brevican, a brain-specific extracellular matrix protein. The cleavage of aggrecan and brevican suggests key roles of this enzyme in arthritic disease and in the central nervous system, potentially, in the progression of glioma.

Ver Producto